在第3、4和5段中增加了详细信息
路透4月25日 - 礼来LLY.N周五表示，已要求欧洲药品监管机构重新审查其对该公司阿尔茨海默氏症药物的意见。
上个月，监管机构否决了该药Kisunla，称其减缓认知能力衰退的能力不足以抵消患者脑部严重肿胀的风险。
礼来公司当时曾表示， (link)，计划向监管机构申请复审。
该机构表示，在收到申请理由后，它将重新考虑自己的意见，并发布对该药物的最终建议。
礼来公司的这种药物已在美国获得批准。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.